Clinical trials: Physician Behavior
Attention Deficit Hyperactivity Disorder
An Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder
A single arm, open-label, phase 3 multicenter study to evaluate the effectiveness and tolerability of atomoxetine (given once daily, target dose 1.2 mg/kg/day), as perceived by patients, parents and physicians, and its impact on…
- Trial name
- NCT00191516
- Testing
- Atomoxetine
- Where
- Germany
- Volunteers
- 257 people
- Sponsor
- Eli Lilly and Company
Quality of Life
Medical Affairs Pharmaceutical Physician Work-related Quality of Life (MAPPWrQoL) Instrument Development and Patient Registry (MAPPWrQoLReg)
Existing evidence has shown that medical affairs pharmaceutical physicians (MAPPs), are a core function within the pharmaceutical industry.
- Trial name
- NCT05123846
- Where
- United Kingdom
- Volunteers
- 180 people
- Sponsor
- Medialis Ltd.
Depression
Major Depressive Disorder (MDD)
The purpose of this study is to assess the effectiveness of systematic screening for depression in high-risk patient participants in everyday clinical practice.
- Trial name
- NCT01662817
- Testing
- Intervention, Control
- Where
- Spain
- Volunteers
- 525 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Contraception
Assess Satisfaction of Patients and Physicians With Results of Yaz Plus Treatment for 13 Cycles
Local prospective multicenter non-comparative non-interventional observational study. It's planed to assess satisfaction of patients and physicians with results of Yaz Plus treatment for 13 cycles in real practice.
- Trial name
- NCT02159261
- Testing
- BAY98-7071_EE20/DRSP/L-5-MTHF
- Where
- Russia
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Bayer
Depression, Type 2 Diabetes Mellitus
Physician Led Counseling in Management of Depression in Type 2 Diabetes Mellitus
There is a high prevalence of depression in patients with diabetes mellitus. Depression has been shown to be associated with poor self-management (adherence to diet, exercise, checking blood glucose levels) levels in patients…
- Trial name
- NCT02185482
- Testing
- Physician Supported Care, Usual care
- Where
- 2 sites in India
- Volunteers
- 150 people
- Sponsor
- Adwin Life Care
Cosmetic Procedures
Cosmetic Dermatology Study
This study aims to understand the impact of VeinViewer technology during routine cosmetic and dermatologic procedures.
- Trial name
- NCT02200471
- Testing
- VeinViewer
- Where
- 2 sites in United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Christie Medical Holdings, Inc.
Schizophrenia, Bipolar Disorder
Physician Survey on Monitoring of Patients Treated With Quetiapine
A physician survey to document receipt of metabolic educational materials and assess behavior of physicians in following messages communicated through the educational materials
- Conditions
- Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT01795326
- Volunteers
- 800 people
- Sponsor
- AstraZeneca
Schizophrenia, Bipolar Disorder
EMR Data to Assess Monitoring of Patients Treated With Quetiapine
A study to evaluate the effectiveness of an update of educational materials with respect to evaluation of monitoring of metabolic parameters
- Conditions
- Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT01793324
- Volunteers
- 6,153 people
- Sponsor
- AstraZeneca
Asthma
A Study for the Assessment of the Words Used by Patients and Physicians to Express Asthma Symptoms
The purpose of the study is to evaluate the concordance of the most frequently used words by the patients and the physicians to express asthma symptoms and the limitations of daily activities caused by asthma.
- Trial name
- NCT00986219
- Where
- 40 sites in Greece
- Volunteers
- 696 people
- Sponsor
- AstraZeneca
Diabetes, Hypertension
Quality IQ Patient Simulation Physician Practice Measurement and Engagement
This study will test the quality of physician care decisions using a patient-simulation based measurement and feedback approach that combines multiple-choice care decisions with real-time, personalized scoring and feedback.
- Conditions
- Diabetes, Hypertension, Depression, Osteoarthritis
- Trial name
- Q-IQ (NCT03800901)
- Testing
- Continuing Medical Education, Quality IQ Patient Simulations
- Where
- United States
- Volunteers
- 187 people, healthy volunteers welcome
- Sponsor
- Qure Healthcare, LLC
Multiple Sclerosis
A Study to Evaluate the Real-world Experience and Satisfaction Associated With Ofatumumab
The aim of this study was to assess physician and patient satisfaction with ofatumumab using data collected from physicians and their multiple sclerosis (MS) patients in real-world clinical practice across the United Kingdom…
- Trial name
- NCT07504783
- Where
- Switzerland
- Volunteers
- 261 people
- Sponsor
- Novartis Pharmaceuticals
Attention Deficit Hyperactivity Disorder
An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity Disorder
A single arm, open-label, phase 3 multicenter study to evaluate the effectiveness and tolerability of atomoxetine (given once daily, target dose 1.2 mg/kg/day), as perceived by patients, parents and physicians, and its impact on…
- Trial name
- NCT00191737
- Testing
- Atomoxetine
- Where
- 2 sites in Germany
- Volunteers
- 147 people
- Sponsor
- Eli Lilly and Company
Chemotherapy-induced Febrile Neutropenia
Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.
This is a prospective observational study investigating how physicians assess the risk of febrile neutropenia (FN) developing in patients who will receive chemotherapy.
- Trial name
- NCT01813721
- Where
- 90 sites in Australia, Austria and 9 more
- Volunteers
- 1,007 people
- Sponsor
- Amgen
Hypoparathyroidism
A Survey to Assess Participants' and Physicians' Knowledge, Attitudes and Behavior When Using NATPARA
This main aim of this study is to check the level of knowledge and assess attitudes and behaviors of both participants and prescribing physicians regarding the risks and safe use of NATPARA.
- Trial name
- NATPARA KAB (NCT05556629)
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Shire